OncoBEAM testing for Metastatic Colorectal Cancer

Directing therapy

Normanno N, Esposito Abate R, Lambiase M, et al. (2018) RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Annals of Oncology. 29(1):112-118. Links: Pubmed Free PDF
Klein-Scory S, Maslova M, Pohl M, et al. (2018) Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. Translational Oncology. 11(2):213-220. Links: Pubmed Free PDF
Schmiegel W, Scott RJ, Dooley S, et al. (2017) Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Molecular Oncology. 11(2):208-219. Links: Pubmed Free PDF
Grasselli J, Elez E, Caratù G, et al. (2017) Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Annals of Oncology. 28(6):1294-1301. Links: Pubmed Free PDF

Tabernero J, Lenz HJ, Siena S, et al.(2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16(8):937-48. Link: Pubmed

 Van Cutsem E, Lenz HJ, Köhne CH, et al. (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol.33(7):692-700. Links: Pubmed Free PDF

Bokemeyer C, Köhne CH, Ciardiello F, et al. (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51(10):1243-52. Link: Pubmed 

Sorich MJ, Wiese MD, Rowland A et al. (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 26(1):13-21. Links: Pubmed Free PDF

Ciardiallo F, Lenz HJ, Koehne CH, et al.(2014) Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.  J Clin Oncol.  2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl Link: Abstract

Monitoring Resistance

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, et al. (2018) Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Annals of Oncology. 29(1):119-126. Links: Pubmed Free PDF
Corcoran RB, André T, Atreya CE, et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer. Cancer Discovery. 8(4):428-443. Links: Pubmed Free PDF
Vidal J, Muinelo L, Dalmases A, et al. (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Annals of Oncology. 28(6):1325-1332. Links: Pubmed Free PDF
Toledo RA, Cubillo A, Vega E, et al. (2017) Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 8(21):35289-35300. Links: Pubmed Free PDF
Morelli MP, Overman MJ, Dasari A et al. (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 26(4):731-6. Link: Pubmed

Misale S, Yaeger R, Hobor S, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532-6. Links: Pubmed Free PDF

Diaz L, Williams R, Wu J, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537-40. Links: Pubmed Free PDF

Diehl F, Schmidt K, Choti, M, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med. 14(9):985-90. Links: Pubmed Free PDF